HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Rose Sheet

Executive Summary

Actress Geena Davis will host 2006 FiFi Awards April 3 in New York City, Fragrance Foundation announces. In addition, Sarah Jessica Parker, whose namesake scent is nominated as women's luxe fragrance of the year, will be a presenter. Evelyn Lauder will receive a Lifetime Achievement Award during the ceremony, which honors women's and men's fragrances in categories like Noveau Niche, Luxe and Popular Appeal. Fragrance Foundation announced FiFi finalists Feb. 28 (1"The Rose Sheet" March 6, 2006, In Brief)...

You may also be interested in...

FiFi finalists

Chanel's Allure Sensuelle, Coty Prestige's euphoria Calvin Klein and Lovely Sarah Jessica Parker, Elizabeth Arden's fantasy Britney Spears, Estee Lauder's Island Michael Kors and L'Oréal's Ralph Lauren Pure Turquoise are finalists for Fragrance of the Year - Women's Luxe, Fragrance Foundation announces Feb. 28. Fragrance of the Year - Men's Luxe finalists are Bulgari's Aqua Pour Homme, L'Oréal's Armani Code and Polo Black, Procter & Gamble Prestige's Baldessarini Del Mar, Estee Lauder's DKNY Be Delicious Men and YSL Beauté's Z Zegna By Ermenegildo Zegna. Nominees for Best National Advertising Campaign - Print are euphoria Calvin Klein, L'Oréal's Flowerbomb by Viktor & Rolf, Lovely Sarah Jessica Parker, Polo Black, Pure Turquoise and Estee Lauder's Youth Dew Amber Nude. Awards for those categories, as well as for Noveau Niche, Popular Appeal, Private Label/Direct Sell fragrances and others, will be presented during the FiFi Awards in New York City April 3...

Bristol/Exelixis Detail Survival Benefit For Opdivo/Cabometyx In Renal Cancer

Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.

Finance Watch: 2020 IPOs Surpass 2019 Total With 52 To Date

ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts